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Abstract
Despite significant research efforts aimed at understanding the neurobiological underpinnings of psychiatric disorders, the
diagnosis and the evaluation of treatment of these disorders are still based solely on relatively subjective assessment of
symptoms. Therefore, biological markers which could improve the current classification of psychiatry disorders, and in
perspective stratify patients on a biological basis into more homogeneous clinically distinct subgroups, are highly needed.
In order to identify novel candidate biological markers for major depression and schizophrenia, we have applied a focused
proteomic approach using plasma samples from a large case-control collection. Patients were diagnosed according to DSM
criteria using structured interviews and a number of additional clinical variables and demographic information were
assessed. Plasma samples from 245 depressed patients, 229 schizophrenic patients and 254 controls were submitted to
multi analyte profiling allowing the evaluation of up to 79 proteins, including a series of cytokines, chemokines and
neurotrophins previously suggested to be involved in the pathophysiology of depression and schizophrenia. Univariate
data analysis showed more significant p-values than would be expected by chance and highlighted several proteins
belonging to pathways or mechanisms previously suspected to be involved in the pathophysiology of major depression or
schizophrenia, such as insulin and MMP-9 for depression, and BDNF, EGF and a number of chemokines for schizophrenia.
Multivariate analysis was carried out to improve the differentiation of cases from controls and identify the most informative
panel of markers. The results illustrate the potential of plasma biomarker profiling for psychiatric disorders, when conducted
in large collections. The study highlighted a set of analytes as candidate biomarker signatures for depression and
schizophrenia, warranting further investigation in independent collections.
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Introduction
The search for peripheral markers for psychiatry disorders has
been underway for many years, but, in spite of these efforts, a non-
invasive blood-based test that could be used for diagnosis, or help
to stratify patients based on disease subtype remains elusive [1].
Previous experimental attempts to generate reliable blood-derived
markers have selected candidate biomarkers based on current
models of disease pathogenesis. For example, studies in depression
and schizophrenia have tested specific biomarkers based on the
hypothesis of monoamine dysfunction, the immuno-inflammatory
hypothesis, the neuroendocrine and the neuroplasticity hypothesis
[2]. These investigations, usually relying on the selection of single
readouts, have generated a number of putative biomarkers which
still require replication in larger studies. Due to the presumed high
level of etiologic heterogeneity and the overlap of dimensions
across mood disorders and schizophrenia, standalone markers are
unlikely to be specific or applicable on a wide scale and for a wide
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range of patients. For both depression and schizophrenia,
monoamine-related markers have been studied with only partial
success in terms of specificity of the marker, or replication of the
findings. More recently, a number of studies have been carried out
to evaluate the potential of neurotrophin markers such as BDNF in
different psychiatric diseases, again resulting in evidence of
association but also with many non-specific or conflicting findings
(for some examples of discrepancies in schizophrenia and autism,
see [2]). For depression, the most robust laboratory finding is
probably the HPA dysfunction of depressed patients during acute
phase, which has led to the development of neuroendocrine
challenge tests as putative biomarkers with potential application in
clinical context [3].
Another interesting line of research has focused on inflamma-
tory-related markers, based on the evidence of reciprocal
communication between immune and nervous systems and of
altered immunological state in psychiatry diseases. For depression
in particular a ‘‘cytokine hypothesis’’ has been developed that
associates the dysregulation of the immuno-inflammatory system
with the aetiology and the pathophysiology of major depressive
disorder [4]. The theory is supported by the evidence of positive
correlation between circulating levels of pro-inflammatory cyto-
kines, acute phase proteins and chemokines and symptoms of
depression and fatigue in humans and preclinical species. So far,
the majority of studies in psychiatry have investigated small
cytokine subsets, mainly monocytic pro-inflammatory cytokines
such as IL-1, IL-6 and TNFa (see [5] for an analysis of studies of
inflammatory markers in antidepressant treatment). Recently a
larger panel of pro- and anti-inflammatory cytokines was
measured in a case/control population of major depressive
disorders (MDD) (49 cases and 49 controls) showing elevation of
a number of additional cytokines not previously implicated in
MDD, as well as of some previously untested chemokines [6].
These promising data are supportive of the application of wider
profiling approaches to the identification of biomarker panels as
diagnostic tools for the classification of psychiatric diseases.
Multi-analyte and array profiling techniques enable the
simultaneous detection of hundreds of proteins with high
sensitivity and accuracy and can be successfully applied to identify
biomarkers (or clusters of biomarkers) that correlate with disease
[7]. We describe here the application of a large protein profiling
investigation for the identification of novel peripheral markers for
depression and schizophrenia, based on a focused proteomic
approach. A large number of plasma samples selected from well
characterized psychiatric disease collections were submitted to
protein profiling using a commercially available multi-analyte
protein panel that contains a number of cytokines, chemokines,
neurotrophins and hormones involved in pathways hypothesized
to be involved in the pathophysiology of psychiatric diseases. The
results obtained suggest that peripheral signatures for depression
and schizophrenia may be identified by exploiting large clinical
collections.
Methods
Patients
The present study was performed on plasma extracted from a
subset of clinically well characterized cohorts of patients diagnosed
with MDD and schizophrenia that were collected as part of larger
genetic initiatives [8,9].
The detailed clinical findings of the full MDD and schizo-
phrenia cohorts have been reported elsewhere [8,10]. All
participants in these studies, which were approved by their
respective local Ethics Boards, received a detailed description of
the goals and funding of these studies and provided a written
informed consent.
Major Depressive Disorders. A total of 1022 Caucasian
patients with recurrent MDD were recruited at the Max-Planck
Institute of Psychiatry in Munich, Germany and at two satellite
recruiting hospitals (BKH Augsburg and Klinikum Ingolstadt) in
the Munich area. Patients were evaluated using the semi-
structured Schedule for Clinical Assessment in Neuropsychiatry
(SCAN) instrument, administered by experienced research
assistants who had received proper training at WHO Training
and Research Centers. Patients were included in the study if they
received a diagnosis of recurrent MDD (i.e. at least two separate
episodes of depression) according to DSM-IV or ICD-10. Patients
were excluded from the study if they had experienced mood
incongruent psychotic symptoms, a lifetime history of intravenous
drug use or diagnosis of drug dependency, depression secondary to
alcohol or substance abuse or depression as clear consequence of
medical illnesses or use of medications. Patients with co-morbid
anxiety disorders, with the exception of obsessive compulsive and
post traumatic stress disorders, were included. Patients with
diagnosis of schizophrenia, schizoaffective disorders and other axis
I disorders were excluded from the study.
Schizophrenia. Patients were assessed at the Ludwig-
Maximilian University in Munich Germany. A total of 499
unrelated patients received a DSM-IV diagnosis of schizophrenia
according to The Structured Clinical Interview for DSM-IV,
SCID. Patients with a diagnosis of schizoaffective disorder or
reported to be an intravenous drug user or with a lifetime
diagnosis of dependency were excluded. All patients were at least
18 years of age and Caucasians. Detailed medical and psychiatric
history interviews included the administration of Positive and
Negative Symptom Scale (PANSS).
Controls. A total of 968 Caucasian non-affected individuals
were recruited at the Max-Planck Institute of Psychiatry in
Munich, Germany. All subjects were selected from a Munich-
based community sample. They were screened for the presence of
anxiety and mood disorders using the Composite International
Diagnostic Screener [11]. Only individuals without mood and
anxiety disorders and schizophrenia at screening were included.
Sample Selection
To reduce the heterogeneity of patients and controls, plasma
samples were selected from the available collection based on a
number of available clinical and demographic criteria. Subjects
with comorbidities for the following major medical conditions that
could have an overt impact on the protein profile were excluded:
cancer, multiple sclerosis, Parkinson’s disease, rheumatoid arthri-
tis, inflammatory bowel disorder (Chron’s disease, ulcerative
colitis), psoriasis, emphysema, chronic bronchitis, hayfever,
diabetes type 1 (early onset), diabetes type 2 (late onset), heart
attack, angina, stroke. In addition, patients older then 80 and with
BMI ,18.5 or .40 were excluded. In the depression and control
data set, patients smoking more than twenty cigarettes/day were
also excluded.
The demographics and main clinical characteristics of the
samples submitted to protein profiling analysis are reported in
Table 1.
Plasma Samples
Blood (approximately 7.5 ml) was obtained by forearm vein and
drawn in EDTA containing tubes for biomarker studies. The
samples were centrifuged for 10 min at 4C and the resulting
plasma aliquoted into Eppendorf tubes, which were frozen
immediately at 280uC.
Psychiatry Plasma Biomarkers
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Biomarker Profiling
A total of 741 samples were analysed by Rules Based Medicine,
Inc with the Multi Analyte Profiling Human MAP, a quantitative,
multiplexed immunoassay based on Luminex xMAP technology
[12,13] which measures a battery of analytes including chemo-
kines, cytokines, hormones, growth factors, antigens and other
protein markers. The following 79 analytes were assessed by using
the Human MAP version 1.5: a-1 Antitrypsin; Adiponectin; a-2
Macroglobulin; AFP; Apolipoprotein A1; Apolipoprotein CIII;
Apolipoprotein H; b-2 Microglobulin; BDNF; Complement 3; CA
125; CA 19–9; Calcitonin; CEA; CK-MB; CRP; EGF; ENA-78;
Endothelin-1; Eotaxin; Erythropoietin; FABP; Factor VII; Ferri-
tin; FGF basic; Fibrinogen; HGH; GM-CSF; GST; ICAM-1; IgA;
IgE; IgM; IL-1 a; IL-1 b; IL-2; IL-3; IL-4; IL-5; IL-6; IL-7; IL-8;
IL-10; IL-12p40; IL-12p70; IL-13; IL-15; IL-16; Insulin; Leptin;
Lipoprotein (a); Lymphotactin; MCP-1; MDC; MIP-1 a; MIP-1 b;
MMP-2; MMP-3; MMP-9; Myoglobin; PAI-1; PAP; PSA, Free;
RANTES; Serum Amyloid P; Stem Cell Factor; SGOT; TBG;
Tissue Factor; TIMP-1; TNF RII;TNF-a; TNF-b; Thrombopoi-
etin; TSH; VCAM-1; VEGF; vWF (see Table S1, Supporting
Information for additional information). Samples were processed
and analyzed according to RBM standard operating procedures.
All samples were stored at 280uC until tested. The samples were
thawed at room temperature, vortexed, spun at 13,0006g for 5
minutes for clarification and volume was removed for MAP
antigen analysis into a master microtiter plate. Using automated
pipetting, an aliquot of each sample was introduced into one of the
capture microsphere multiplexes of the Human Antigen MAP,
thoroughly mixed and incubated at room temperature for 1 hour.
Multiplexed cocktails of biotinylated, reporter antibodies for each
multiplex were then added robotically and after thorough mixing,
were incubated for an additional hour at room temperature.
Multiplexes were developed using an excess of streptavidin-
phycoerythrin solution which was thoroughly mixed into each
multiplex and incubated for 1 hour at room temperature. The
volume of each multiplexed reaction was reduced by vacuum
filtration and the volume increased by dilution into matrix buffer
for analysis. Analysis was performed in a Luminex 100 instrument
and the resulting data stream was interpreted using proprietary
data analysis software developed at Rules-Based Medicine (RBM
Plate Viewer version 1.1.1). For each multiplex, both calibrators
and controls were included on each microtiter plate. 8-point
calibrators were run in the first and last column of each plate and
3-level controls were included in duplicate. Testing results were
determined first for the high, medium and low controls for each
multiplex to ensure proper assay performance. Unknown values
for each of the analytes localized in a specific multiplex were
determined using 4 and 5 parameter, weighted and non-weighted
curve fitting algorithms included in the data analysis package. The
plasma samples were run in duplicate and data reported back as
concentrations (average of two independent measures), together
with normative data such as least detectable dose (determined as
the mean 63 standard deviations of 20 blank readings) and lower
assay limit (assay working sensitivity defined by the lowest
concentration calibrator used for quantitation). Any value above
the LDD will possess coefficients of variation (CV) less than 20%.
Data Analysis
As each of the protein analytes is tested by a specific
immunoassay, the resulting data have potentially different
statistical properties and therefore different required data
transformations prior to analysis. Automated procedures were
considered unsuitable and appropriate transformations (none,
square root or log) were selected by visual inspection of the group-
wise distribution of the raw data for each single protein.
In addition, two different approaches were applied to recover
part of the potential information carried out by the protein
analytes that showed a significant percentage of samples with
values below detection limit in at least one of the groups
(depressed, schizophrenics and controls), with the percentage of
‘‘censored values’’ differing between the groups. In the first
approach the value below the threshold of detection limit
(‘‘censored value’’) was substituted by the most observed low
value in the set. In a second approach, part of the censored signal
was recovered by the mean-median imputation technique. This
method exploits the property that the underlying data distribution
is broadly symmetric after data transformation and hence
imputation values are selected to force the mean and median
values to coincide. Other additional methods including truncated
normal maximum likelihood (Tobit’s method) and Random
Forests were also performed. Where minimum value imputation
analysis was performed, our results were additionally validated by
a stability analysis imputing changing fractions of the minimum
values obtained for each response, which confirmed our main
analysis.
Statistical Tests
Statistical analysis was performed by a combination of
univariate analysis, i.e. t-tests, analysis of variance (ANOVA)
and multivariate analysis, including Principal Component Analysis
(PCA), PCA followed by partial least squares discriminant analysis
(PLS-DA), and a Random Forest algorithm. Statistical analyses
were performed by using SIMCA-P+ version 11 (Umetrics AB,
Umea˚, Sweden) and SAS 9.1 (SAS Institute Inc., Cary, NC, USA)
software. RF and LDA analysis were performed using R version
2.6.2 (R Foundation for Statistical Computing, Vienna, Austria).
For univariate methods, both ANOVA and non-parametric
approaches were used in addition to standard transformation and
rank transformations, minimum value and mean-median imputa-
tion. Similar approaches were followed for multivariate analysis
leading to PCA and PLS-DA. Receiver Operating Characteristic
(ROC) plots [14] were derived from linear discriminative analysis
(LDA) based on the top findings from the PLS approach. Random
forest (RF) algorithm [15] based on cross validation with a training
set and a test set was applied to generate an independent
multivariate discriminative model, for which ROC curves were
also produced. For markers of interest, correlation with disease
state was calculated by performing Spearman’s correlation tests.
Table 1. Demographic data of cases and controls submitted
to biomarker analysis.
Parameter Depression Schizophrenia Controls
Total number (N) 245 229 254
Gender (M/F) 78/167 115/114 81/173
Age (mean6SD) 53.2614.3 37.8610.7 48.9614.2
BMI (mean6SD) 25.964.0 26.664.9 24.263.4
N of smokers
(current/former/never)
38/32/177 130/34/65 42/88/124
N of treated*/untreated 225/20 205/24 1/253
*Treatments defined as monoamine re-uptake inhibitors, tryciclic
antidepressants, monoamine oxidase inhibitors, mood stabilizers, typical and
atypical antipsychotics.
doi:10.1371/journal.pone.0009166.t001
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Results
Univariate Analysis
Univariate analysis was carried out to identify single protein
signals that are associated with disease status and to establish
information and methodology applicable to multivariate approach
in subsequent analysis.
Three different approaches were used: i) t-tests and standard
ANOVA on log or square root ad-hoc transformed protein values,
and replacement of values below detection limit by the lowest valid
observed value; ii) ANOVA after first-ranking data transforma-
tion; iii) a non-parametric version of the t-test (Wilcoxon). All three
approaches gave similar results (not shown) which led us to use the
first two data transformation approaches for subsequent multivar-
iate analysis.
Results from t-tests showed strong differences between the
control and both disease groups, with larger differences observed
for schizophrenia cases. Analysis of parametric, non-parametric
and rank transformation results shows that there are many more
significant p-values than what would be expected by chance (see
Supporting Information, Figure S1).
Figure 1 shows the relative difference (fold changes with
confidence intervals) for each single protein when comparing
samples from MDD versus controls and samples from schizophre-
nia versus controls, by gender. To obtain a common scale, all
results presented are based upon log transformed data. As it can be
seen, many protein differences have statistical significance well
above the highly conservative Bonferroni correction threshold
(represented by the vertical line, i.e. a p-value threshold of 5%
significance level corrected for multiple testing), in particular for
schizophrenia. For depression, the analyte that showed the highest
difference between cases and control was insulin (in particular for
female subjects). A significant and consistent increase was also
observed for MMP-9, with p-values ranging between 10210 and
10220. For schizophrenia, BDNF, Rantes and EGF gave the
strongest signals, with p-values ranging approximately between
10230 and 10260.
Full data (p-values by analyte and by group, from LSD test on
transformed data) are included in Table S2 in Supporting
Information. Figure 2 shows the combined plot (for both MDD
and schizophrenia) corresponding to some of the analytes with
highly statistically significant findings in both comparisons,
according to univariate analysis. For some protein analytes, the
observed change is clearly more marked in one of the disease
groups, such as in the case of BDNF and EGF for schizophrenia
and insulin for depression.
A formal analysis was also performed on additional demo-
graphic covariates to investigate the potential occurrence of
stratification effects impacting the above results, due to the
differences in gender ratio or mean BMI and age between groups.
Results of this investigation are shown in Supporting Information,
Table S3, which reports all p-values obtained for disease effect, for
demographic effects (age, gender and BMI), for disease effect after
inclusion of demographic covariates, and disease/covariate
interaction. The above analysis indicates that some of the putative
MDD- or schizophrenia-associated markers display also significant
association with demographic covariates, such as insulin with BMI
or BDNF with age. However, the comparison of simple p values
for disease effects with p values obtained after fitting covariate
effects indicates that there are no major deviations from the
original results, at least for the top findings (see also Supporting
Information, Figure S2). For instance, age effects do not appear to
modify substantially the highly significant associations found for
BDNF, RANTES, EGF, TIMP-1, ENA-78 and MDC levels with
schizophrenia. For depression, the insulin elevation in patients
compared with controls remains highly significant after fitting
BMI, as well as across different BMI ranges (not shown). Further
analyses were carried out for insulin, to assess potential dietary and
site confounders that might have affected the finding of its
elevation in depressed patients. By adjusting for time since last
Figure 1. Relative change of protein markers in MDD or schizophrenia against their p-values. Plot of relative changes for measured
analytes in depression (a) and schizophrenia (b) against their p-values. The Y axis reports the relative increase (or decrease) as the ratio (and the
confidence interval) based on analysis of log-transformed data from cases/controls. Reference vertical line corresponds to p-value threshold at a 5%
significance level, after correction for multiple testing. Male and females are computed and reported separately.
doi:10.1371/journal.pone.0009166.g001
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meal (minutes) and blood glucose levels available from the clinical
chemistry panel, the observed elevation remains highly significant
(see Supporting Information, Figure S3).
Multivariate Analysis
Multivariate analysis was also carried out to explore correlations
within the dataset, and to identify whether multiple analytes could
increase the discrimination between cases and controls. The
analysis was performed in two stages: i) principal components
analysis (PCA) for unsupervised analysis of the full dataset, aimed
at determining whether a multivariate signal was present; ii) partial
least squares discriminant analysis (PLS-DA) to help identifying
the identity of the proteins responsible for the separation.
Figure 3 shows a PCA plot obtained by using SIMCA. The
graph is obtained by the pragmatic approach of replacing values
below detection limit with the lowest robust value measured for
each protein, and results are in close agreement with those
obtained using other approaches (e.g. with rank observations, data
not shown). Similar to the results of the univariate analysis, a
strong separation can be observed, in particular for schizophrenia
samples.
It should be noted that the above graph were produced by PCA
without previous disease classification information, in contrast to
partial least squares (PLS) approach, which is known to split
classified groups even from random data sets. Having established a
separation by PCA, the step of PLS-discriminant analysis was used
solely to compute a series of scores (variable importance in the
projections, or VIPs) to assess the contribution of individual
proteins to these dimensions. The two graphs in Figure 4 (a,b)
show the contribution of information from each individual
variable to the overall control-depression and control-schizophre-
nia separation by PLS discrimination analysis.
In Figure 5, the contribution of each single analyte to the
separation of disease from control samples (VIP) are plotted for
schizophrenia and depression on the y- and x- axis, respectively, to
provide a visual representation of the relative specificity of the
findings. The analytes highlighted in the box could be considered
as the best informative or diagnostic set to discriminate disease
from controls in the two categories. Proteins falling in the
overlapping region may contribute to the separation but can be
expected to be less specific markers.
To assess the capability of our diagnostic set of marker to
discriminate correctly between cases and controls, we have derived
ROC plots [14] based on a linear discrimination analysis model
(LDA) built upon the 10 markers with the highest contribution as
determined by PLS-DA (see VIP plots). As it can be seen in
Figure 6, the selected analytes are showing a good degree of
selectivity/specificity pair for MDD/control and a superior
Figure 2. Plasma protein markers with highest significance in MDD and schizophrenia. Box plots of individual analytes with high
univariate significance. Where data below detection limit were present (see bar charts on bottom row for EGF and MMP-9) they are replaced by the
lowest observed value to generate the box plots. The bracketed values in the titles refer to the data transformation, if applied, and the sequence
number in the original dataset. The white line corresponds to the median, whilst the full box represents the central 50%.
doi:10.1371/journal.pone.0009166.g002
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discriminative power for SCZ from controls, with a true positive
rate greater than 90% when setting the criterion for false positive
at 5% (specificity.95%). To corroborate the above findings by an
independent method, we have applied to the data a random forest
(RF) algorithm, which included variable selection and cross
validation with a training set and a test set. The discriminative
model generated by RF and the corresponding ROC curves
(Figure S4, Supporting Information) basically confirm the findings
obtained by more traditional multivariate PCA and PLS analysis.
A number of ad hoc tests were then performed in order to verify
the impact of some covariates on the separations observed in PCA.
To assess the possibility that potential confounders could be
responsible for the strong separation observed between schizo-
phrenics and controls we have analysed PCA plots generated by
the multivariate analysis in the context of additional parameters,
including psychotropic drug treatment. The data in Figure 7, for
instance, suggest that the modulation of the protein profile in
samples from schizophrenic patients appears to be independent
from treatment, as non-medicated patients could not be separated
from patients medicated with different antipsychotics, neither a
specific antipsychotic treatment group was observed.
Correlation Analysis
The potential correlation between the levels of the identified
markers and disease severity was assessed for the schizophrenia
subset, for which PANSS data obtained at the sampling visit were
available for all patients. Results obtained by performing a
Spearman’s correlation test on analytes identified by the previous
approach (see Figure S5, Supporting Information), particularly in
view of the large sample sizes used, do not provide strong evidence
of a significant correlation of the protein values with the severity
scale, further suggesting that the signal identified are likely to be
trait markers.
Discussion
The study reported here is one of the first focused clinical
proteomic investigations carried out in a large clinical population
of psychiatric patients, based on the profiling of a number of
proteins belonging to pathways previously shown to be involved in
the pathophysiology of either depression or schizophrenia (such as
growth factors, cytokines) or previously untested. The results
obtained have highlighted a number of differences between cases
and controls which is well above what could be expected under the
null hypothesis, with several protein analytes that appeared to be
specifically modulated in one of the two disease groups. As shown
by the univariate analysis, the significance of the observed
differences is higher for schizophrenia than depression, resulting
with a very high discriminative power of the panel for SCZ from
controls as shown by the ROC plots.
In depression, univariate analysis highlighted a significant
difference in particular for insulin and matrix metallo-proteinase
9 (MMP-9), which was also highlighted by the multivariate
approach. Insulin was the marker with the highest statistical
significant finding, shown to be increased in MDD cases compared
to controls. When insulin data were stratified by glucose and time
from last meal to compensate for potential post-prandial
confounder effects and the effects of glucose-insulin homeostasis,
the results remained statistically significant. The observed data are
consistent with the observation that depression is frequently linked
with insulin resistance: reduced glucose utilization and elevated
insulin secretion following glucose administration have been
shown in depressed patients [16,17]. The high comorbidity
between type 2 diabetes and depression [18] and the strong
association between depression and metabolic syndrome [19] are
further justifications to support the above hypothesis. More
recently, evidence of a bidirectional relation between hypercorti-
Figure 3. PCA plot showing the separation of schizophrenia samples from controls and MDD. PCA plot obtained by using SIMCA, where
the 1st and 3rd components of the model (t[1] and t[3], respectively) are shown. The graph is obtained by replacing values below detection limit with
the lowest value measured for each protein (conservative approach).
doi:10.1371/journal.pone.0009166.g003
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Figure 4. Contribution from each individual marker to case-control separation from PLS discrimination analysis. Variable Importance
of Information (VIP) plot ranking markers for their contribution to case-control separation from PLS discrimination analysis. A: MDD; B: schizophrenia.
Larger values on the left indicate more important contributions.
doi:10.1371/journal.pone.0009166.g004
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solemia in depressed patients and poor glycemic control was
provided [20]. The studies reported so far highlight an impairment
of insulin sensitivity in depressed patients which is state-dependent
[21], and no detectable difference in 24 h mean glucose and
insulin levels from healthy controls [20]. However, due to the
increased statistical power of the current study, one cannot exclude
that the difference in physiological insulin secretion observed is
reflecting an underlying trait of depression associated with
impaired glycemic control. The high significance of the finding
remained after the inclusion of BMI as a covariate (see Supporting
Information) and after inclusion of potential dietary confounders
suggesting that the increase in physiological insulin levels were not
driven primarily by dietary or BMI differences across sites or
between cases and controls.
Our analysis also revealed that members of the extracellular
proteolytic system, composed of matrix metalloproteinases
(MMPs) and their endogenous tissue inhibitors (TIMPs), were
modulated in the two disease groups (increased MMP-9 levels,
and, to a lesser extent, decreased MMP-2 levels in MDD;
increased TIMP-1 levels and MMP-9 levels in schizophrenia).
MMPs display a key role in central nervous system as they are able
to process several proteins crucial for synaptogenesis, synaptic
plasticity, and long-term potentiation (LTP) [22]. MMP-9 was
specifically shown to regulate synaptic plasticity in the hippocam-
pus by gain- and loss-of-function studies on LTP in vitro [23,24].
Experimental evidence supports the hypothesis that the MMP/
TIMP ratio modulates neuronal plasticity in learning and memory
processes [25]. TIMP-1, which binds to MMP-9 and regulate its
activity, was indeed shown to be able to prevent MMP-9-
dependent late LTP in the rat medial PFC [26]. MMPs and
TIMPs have been also investigated as potential markers for
dementia, resulting with the identification of altered plasma levels
of MMP-9 and TIMP-1 in Alzheimer’s Disease and vascular
dementia, respectively [27].
MMPs have many other properties, including the ability to
modulate cytokines and growth factors (such as TNF-alpha and
BDNF among others) by processing their proforms into active
forms [22]. Interestingly, similar to what we have found in our
case, patients with metabolic syndrome also display increased
circulating concentrations of pro-MMP-9, MMP-8, and TIMP-1,
which were associated with increased concentrations of pro-
inflammatory mediators and adhesion molecules [28]. Of note,
our supplemental data show a positive association of TIMP-1
levels with age in MDD patients and controls, which is not
detected in the schizophrenia group which has elevated levels in
spite of a lower mean age with respect to controls.
For MDD, several studies suggest a link between circulating
cytokines and depressive episodes. Increased circulating levels of
pro-inflammatory cytokine, acute phase proteins and chemokines
are known to be associated to symptoms of depression and fatigue
in humans and preclinical animal species [4,29,30]. Increased
circulating levels of IL-6 and TNF-a were described in a consistent
susceptible population of patients suffering from Major Depressive
Disorders during the symptomatic episode [31–35] and correlation
Figure 5. Comparing marker contributions to case-control separation for MDD versus schizophrenia. The Variable Importance of
Contribution (VIP) from PLS-DA for each analyte is plotted on X axis for MDD and on the Y axis for schizophrenia. The overlap between the two
groups of markers highlights findings that are in common between the two disease groups.
doi:10.1371/journal.pone.0009166.g005
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between the high levels of IL-6 in the morning and depressive
symptoms were found in MDD patients by Alesci et al. [36].
Successful antidepressant treatments of MDD episodes with SSRIs
or TCAs are associated to the reduction of circulating cytokine
levels, in particular TNF-a [37,38] and IL-6 [39]. A recent meta-
analysis on inflammatory markers in depressed patients has
confirmed a consistent positive association between depression
and IL-6, and IL-1 and the acute phase protein CRP levels in
peripheral blood [40]. In addition, it was shown that major
depression is characterized by an acute phase response, with
elevated levels of positive acute phase proteins [41,42]. Accord-
ingly, we have found a number of acute-phase proteins (a2-
macroglobulin, C-reactive protein and b2-microglobulin) that
contributed to the separation between cases and controls.
However, beside a significant signal obtained by increased TNF-
RII, consistent with recent findings [43–45], we did not observe
pro- and anti-inflammatory proteins amongst the analytes with the
highest contribution to the separation. This may be due to the fact
that IL-6 and TNF-a, the most significant findings according to
the literature, had too many missing values in our dataset to
become significant. A recent analysis of inflammatory markers in
MDD patients using a cytokine panel has confirmed the elevation
of pro-inflammatory interleukins and highlighted abnormalities in
additional factors, such as MIP-1 and eotaxin, not previously
implicated in MDD [6]. When comparing our data with the above
results, we found little degree of overlap. The above observations
may be reconciled by considering that the elevation in these pro-
inflammatory cytokines is thought to be symptom- or state-related,
whilst most MDD cases in the present investigation were sampled
outside the acute episode, resulting with likely markers for trait.
Figure 6. Receiver-operating characteristic (ROC) plot derived
from linear discriminative analysis (LDA) based on the top
findings from the PLS approach. ROC plot of sensitivity (True
Positive Rate, Y-axis) versus 1 – specificity (False Positive Rate, X-axis)
based on a Linear discrimination model (LDA) built upon the 10 markers
with the highest contribution as determined by PLS-DA.
doi:10.1371/journal.pone.0009166.g006
Figure 7. PCA plot showing the lack of separation of untreated from treated schizophrenics by plasma profiling. PCA plot obtained by
SIMCA coded according with the different medications for schizophrenia cases (‘‘C’’ indicates treatment with clozapine, ‘‘A’’ treatment with other
atypical antipsychotics, ‘‘T’’ indicates treatment with typical antipsychotics, ‘‘-‘‘ indicates untreated subjects). The dark blue (untreated, diamond)
schizophrenics samples do not separate out from the whole schizophrenic group. t[1] and t[3] represent the 1st and 3rd component of the PCA model.
doi:10.1371/journal.pone.0009166.g007
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From the analysis of the data from schizophrenia sample, it can
be observed that the strong separation from controls is due to
protein analytes belonging to the growth factors and neurotrophin
family, such as BDNF, EGF or stem cell factor, and to a lesser
extent from member of the chemokine/cytokine family. Neuro-
trophin/growth factor levels were previously reported to be altered
in samples from schizophrenics with respect to control samples in
both peripheral and central tissues. For EGF, decreased levels
were found in serum from schizophrenic patients [46,47], even
though a previous study has failed to show significant differences
between 40 cases and 40 controls [48]. For BDNF, previous
studies in schizophrenia have produced mixed results, with
evidence of increased, decreased, or no change in serum or
plasma BDNF level [47,49–52]. It should be noted that the sample
size of the current study is one order of magnitude larger than the
ones used in previous studies. However we cannot rule out
potential stratification (for example differences in mean age) or site
effects as potential confounders in our study, and further
investigation in separate collections are warranted. In contrast,
for MDD a small but significant overall decrease of BDNF was
found, in line with most clinical observations reported so far [53].
Among proteins belonging to other pathways, a number of
chemoattractants were found to be modulated in schizophrenia
samples, i.e. ENA-78 (Epithelial Neutrophil Activating Peptide-78,
a recently discovered chemoattractant and activator for neutro-
phils, belonging to the IL-8 subgroup of the C-X-C family of
chemokines); CCL5 or Rantes (which functions as a chemo-
attractant for blood monocytes, memory T helper cells and
eosinophils; it is one of the natural ligands for the chemokine
receptor CCR5); MDC (Macrophage-derived chemokine or
CCL22, a functional ligand for the CC chemokine receptor and
a novel chemoattractant for monocytes, monocyte-derived den-
dritic cells, and natural killer cells). Interestingly, alterations in
peripheral chemokine levels have been recently observed in
bipolar and schizophrenia patients [54,55].
All the above analytes contributed to the strong separation
observed between schizophrenic cases and controls, which appears
to be unrelated to treatment regimen. In addition, we have found
some degree of correlation between analytes that significantly
contributed to the separation between schizophrenic and control
samples (not shown), suggesting that the difference in levels
between disease and control samples maybe arise from a
modulation of a common biological mechanism. While one
cannot completely rule out that the observed changes are arising
from technical differences between sites in sampling procedures for
instance, it is difficult to understand how these site effects could
specifically impact only on a subset of correlated analytes. Another
variable to consider in particular for the schizophrenia group is the
significantly higher percentage of active smokers with respect to
controls. However, the plasma levels of the top findings (such as
BDNF, RANTES, TIMP-1, EGF) was still altered in non-smokers,
and an obvious correlation between the number of cigarettes per
day with the marker values in the smoker subset could not be
found (data not shown). After ruling out medication effects, and
considering that we have found no significant correlations with
PANSS values, the observed changes are more likely to reflect an
impairment in pathways that underlie a characteristic trait for
schizophrenic patients (such as neurodevelopmental abnormalities
or aberrant plasticity pathways), or could reflect a chronic systemic
(inflammatory) response.
In conclusion, by applying multi analyte profiling on a large
collection of MDD and schizophrenia, we have identified a pattern
of analytes that appear to discriminate cases from controls. The
analytes that have contributed to the separation belong to
pathways or mechanisms previously known to be involved in the
pathophysiology of the disease (e.g. neurotrophins in schizophre-
nia) or associated to comorbid states (e.g. insulin resistance in
depression). The validity of the findings is supported by the use of
alternative and complementary multivariate statistical approaches
which resulted with similar output. However, there are a number
of limitations of the current study that need to be taken into
account. The primary objective of the collection was the
conduction of genetic association studies. The depression diagnosis
is lifetime and the subjects were in different active disease states
when the samples were taken or the interviews conducted, and
data on the patients’ mood state were not available for analysis.
Accordingly, the study has a limited capacity to identify state or
severity markers but rather biological markers underlying different
disease traits. Cases were recruited from three different study sites
in the same region whereas controls were recruited from one of the
sites, and we have examined differences in the average time of
sampling from the last meal at the different study centres which in
principle could affect some analytes influenced by diet/metabolism
e.g. insulin, blood glucose, leptin. An additional limitation is the
difference in some of the demographic parameters between the
schizophrenic group and the MDD and control groups (in
particular mean age and gender ratio), though the results
remained significant when fitting the specific effect of single
covariates. Finally, all proteins were measured in plasma and,
although changes in peripheral levels may partly reflect changes
occurred in the brain, we can only speculate about the
physiological role of the identified markers in the central nervous
system.
Notwithstanding the above potential limitations, this study
suggests that disease signatures derived from large scale analysis of
blood samples from psychiatric patients may exist and could be
detected by using large and well characterized sample sets. For
schizophrenia, more significant differences have been detected,
which would need to be replicated in a separate cohort to assess
the impact of potential stratification or site effects. Putative marker
sets for disease trait have been identified, that could help to
delineate homogeneous depression or schizophrenia subgroups
based on biological evidence and, in the long term, generate
objective criteria for patient selection. The insight generated from
the current analysis should drive the design of a biomarker panel
to be applied to longitudinal clinic studies for antidepressant and
antipsychotics. In this way, it would be possible to establish if any
of the identified biomarkers also correlate with clinical improve-
ment, setting the basis for the development of a biomarker panel to
assess disease severity. Our results call for further investigation in
other accessible tissues (such as the cerebrospinal fluid) or in other
psychiatric disorders, as well as for replication from independent
groups.
Supporting Information
Table S1 List of markers assessed by the multi-analyte panel
MAP 1.5 and their Least Detectable Dose.
Found at: doi:10.1371/journal.pone.0009166.s001 (0.11 MB
PDF)
Table S2 Univariate analysis full data set. The table reports p-
values by analyte and by disease group, obtained from Least
Significant Difference test on transformed data analysis from
MDD plus controls or SCZ plus controls; minimum value
imputation approach (see Materials and Methods). Standard
errors and difference on transformed scale are reported. For log
transformed data, the difference corresponds to the log of the ratio
between cases and controls.
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Found at: doi:10.1371/journal.pone.0009166.s002 (0.04 MB
XLS)
Table S3 Effect of age, BMI and gender as covariates. The table
reports the results from a more formal analysis performed on
possible demographic covariates to verify if differences in BMI, age
or gender ratio could impact the results obtained by the disease
group analysis. The analysis aimed at verifying if (i) the clinical
parameters chosen where statistically significant and (ii) if their
inclusion significantly changed the results for the disease groups.
Statistical interactions were also tested in these models. Worksheet
1: p values for demographics (gender, age and BMI); from separate
ANOVA analysis based on full dataset (MDD, SCZ and controls).
Worksheets 2–11: simple p values for disease group (t-test),
p values for demographics, p values for disease group after
inclusion of demographics, demographic by group interaction;
from ANOVA on MDD plus controls or SCZ plus controls. More
specifically: effect of gender (Worksheet 2,3); effect of age, linear
model (Worksheet 4,5); effect of age, quadratic model to account
for potential non-linearity (Worksheet 6,7); effect of BMI, linear
model (Worksheet 8,9); effect of BMI, quadratic model to account
for potential non-linearity (Worksheet 10,11)
Found at: doi:10.1371/journal.pone.0009166.s003 (0.17 MB
XLS)
Figure S1 Non-parametric (a) and rank transformation (b)
results referenced against analysis of variance with minimum
value imputation. The observed p-values strongly deviate from the
expected p-values that would be expected by chance, both for
depression (MDD) and schizophrenia (SCZ) samples.
Found at: doi:10.1371/journal.pone.0009166.s004 (0.27 MB
PDF)
Figure S2 Simple p values vs p values after covariate analysis.
Correlations between simple p values and p values after inclusion
of covariates in the analysis.
Found at: doi:10.1371/journal.pone.0009166.s005 (0.21 MB
PDF)
Figure S3 Effect of dietary confounders on insulin levels
(depression samples).
Found at: doi:10.1371/journal.pone.0009166.s006 (0.10 MB
PDF)
Figure S4 Results from Random Forest (RF) algorithm.
Discriminative models based on cross validation with a training
set and a test set generated by RF and relative ROC curves.
Found at: doi:10.1371/journal.pone.0009166.s007 (0.28 MB
PDF)
Figure S5 Correlation with clinical severity (schizophrenia
samples). Results from Spearman’s correlation test run between
protein levels in the plasma and PANSS value for schizophrenic
patients. The central dots are the correlations, and the horizontal
lines their 95% confidence intervals. The twenty analytes with the
highest correlation are shown.
Found at: doi:10.1371/journal.pone.0009166.s008 (0.07 MB
PDF)
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